Imagine a scenario where a simple oversight could lead to devastating consequences, even death. That's the stark reality of melanoma, the skin cancer most likely to land doctors in court. A groundbreaking 95-year analysis of medical malpractice cases reveals melanoma as the top culprit, with delayed or missed diagnoses often proving fatal. But here's where it gets controversial: are family physicians, who bear the brunt of these lawsuits, being unfairly targeted, or does this highlight a critical gap in primary care training? Let’s dive into the details.
TOPLINE:
In a sweeping review spanning 1930 to 2025, melanoma emerged as the most litigated skin cancer, with nearly one-third of cases resulting in death. The primary issue? Failure or delay in diagnosis, a mistake that can have life-altering consequences.
METHODOLOGY:
Researchers scoured the LexisNexis legal database to identify 188 unique medicolegal cases involving skin cancer. These cases were included if physicians were named as defendants and the litigation focused on the diagnosis or management of skin malignancies. The study analyzed case characteristics such as cancer type, practice setting, defendant specialty, allegations, clinical outcomes, and verdicts across the United States.
TAKEAWAY:
Melanoma dominated the litigation landscape, accounting for nearly half (49.5%) of all cases, followed by squamous cell carcinoma (21.6%) and basal cell carcinoma (14.2%). Alarmingly, death was reported in 29.8% of cases, and metastatic disease in 39.9%. The most common allegation was failure or delay in diagnosis (38.1%), followed by treatment errors (24.2%) and misdiagnosis (11.4%). Family physicians were the most frequently sued (27.5%), followed by dermatologists (20.1%) and pathologists (14.4%). Most cases originated in private practices, with New York and California leading the charge. Among closed cases, plaintiffs won only 5.5% of the time, with awards ranging from $10,000 to $4.25 million.
IN PRACTICE:
The study’s authors emphasize that melanoma’s high litigation rate, especially in cases involving metastasis or death, underscores the critical need for early and accurate diagnosis. They argue that this analysis provides a pragmatic look at the real-world risks physicians face, including legal, financial, and psychological burdens. But this is the part most people miss: the study also raises questions about whether primary care providers are adequately equipped to detect melanoma early, or if the responsibility should fall more squarely on specialists.
CONTROVERSY & COMMENT HOOKS:
Is it fair to blame family physicians for missed melanoma diagnoses, or should dermatologists and pathologists share more of the responsibility? And what role does patient education play in early detection? Share your thoughts in the comments—this is a debate that’s far from settled.
SOURCE:
Led by Ghassan Barnawi, MD, of McGill University, the study was published in the Journal of the American Academy of Dermatology on February 20, 2026. It offers a comprehensive look at the intersection of skin cancer, medical practice, and legal accountability.
LIMITATIONS:
The study’s reliance on published court decisions likely underestimates the true burden of malpractice, as settlements and unreported claims were excluded.
DISCLOSURES:
The research received no external funding, and the authors reported no conflicts of interest. This article was crafted with the aid of editorial tools, including AI, and reviewed by human editors to ensure accuracy and clarity.
